Key Takeaways
- Revenue degrew, but recovery underway: FY24 turnover fell 1.3% to ₹708 crores, dragged by contrast media destocking and a customer plant shutdown, yet Q4 sales rebounded 10% QoQ from the Mahad incident low.
- Validation win unlocks a new growth leg: Full customer approval of the iodinated advanced intermediate, with positive use-test trials, sets up a scale-up during this financial year and buffers the contrast media segment.
- A patented cardiovascular molecule is gaining blockbuster momentum: US label expansion to primary treatment, plus anticipated European approval, positions the product for a volume uptick, with management calling it a potential blockbuster.
- Capex cycle is accelerating, not just continuing: The ₹200 crore annual run-rate is now a floor; management is evaluating a much larger plan, and Unit 4 may be upsized to meet CDMO outsourcing demand and provide risk-mitigating duplicate capacity.
- What to watch next quarter: Whether contrast media volumes normalize in Q2 as guided, the pace of iodinated intermediate scale-up, and any formalization of the larger capex plan.
Contrast Media: The Near-Term Drag and the Structural Buffer
- Customer shutdown depressed volumes: One key client took a plant shutdown to expand capacity, impacting shipments over the last couple of quarters. The slowdown is expected to persist for one more quarter, with volumes returning to historical levels from Q3 onwards.
- Destocking added variability: Certain customer actions around destocking and a longer maintenance shutdown disturbed overall shipment patterns. Management expects quarter-to-quarter dispatch variability to ease after Q2.
- Revenue recognition amplified the Q4 dip: Supplies to a key customer are on DAP terms, so revenue is recognized only when material reaches the site. Q4 benefited from a prior-quarter cutoff, but with lower offtake this quarter, the cutoff is now coming down, which will impact Q1 FY25 recognized revenue.
- Production was deliberately curtailed: When offtake goes down, the company does not produce and stock inventory, so finished goods are very much on the lower side this quarter.
- The iodinated advanced intermediate is the structural answer: Validation quantities received full customer approval in Q4, with use-test trials coming out positive. Scale-up will happen during this financial year, and this newer advanced intermediate will act as a buffer to drive potential growth in the segment next financial year.
Shiven Arora: "We have supplied this material for validation in the month of January. And today we have got a full approval from them. So, nothing could go wrong when it comes to the product quality. I think it has been established well. And the use test trials have come out fairly positive. So scale up will happen during this particular financial year."
The Cardiovascular Blockbuster Bet
- Label expansion transforms the molecule's trajectory: US FDA approval in May expanded the indication from secondary to primary treatment, and a similar label expansion is expected in Europe. The data was also presented to the American College of Cardiology, with very high acceptability from both institutions.
- A unique oral adjunct to statins: Management stated there is today no other oral product that can act as an adjunct to statins, creating a differentiated position. The product is patented until 2032, insulating it from generic competition.
- Volume uptick is probable, not quantified: Management acknowledged there could be an uptick in volume from the label expansion but declined to comment further, calling it not prudent. The company has enough capacity to address any increase.
- Dedicated-line efficiencies will drop to the bottom line: As volumes ramp up, a dedicated line and larger batch sizes will kick in, and those efficiencies should go straight into margins.
VK Singh: "It's very difficult to predict how a molecule will behave, but all that we can say is that the data was presented to the FDA and the data was also presented to the American Cardiology College and both institutes which are institutes of international repute there is very high acceptability of this data because of the acceptability of this data the molecule is now indicated not only for secondary use, but as a primary treatment product... there is today no other oral product which can act as an adjunct to the statins. So, there is great potential. And we reckon that this would be a blockbuster."
Margins: An Accounting Aberration Masks Intact Gross Profitability
- Q4 EBITDA dropped on a WIP and finished-goods swing, not on operations: The decline was primarily because overhead got inventoried in the previous quarter and released to the P&L in Q4, as finished goods stock at year-end was lower than the previous quarter. The impact of roughly 4.3% was offset partly by reductions in ocean freight and power costs.
- FY24 EBITDA actually improved: The full-year improvement was driven by a reduction in raw material prices and control on operating expenses, which remained flattish.
- Raw material tailwind should sustain: Almost all key raw materials saw a marginal price decline during the year, and management believes this trend should continue, helping sustain gross margins.
- FY25 margin mix will shift: With higher growth expected in the PI-API segment, gross margins may go down by a percent or two from current levels. Employee costs will also be significantly higher as the company adds senior management, execution-level people, and expands R&D further.
Ganesh Karuppannan: "This has nothing to do with our actual gross margin. That is intact. But this aberration has occurred only because our finished goods stock end of the year is lower than the previous quarter."
Capex and Capacity: Building for an Inflection
- The ₹200 crore annual floor: At least ₹200 crores per annum is committed for the next two years on existing units.
- Unit 2 Ambernath block is imminent: The block will be ready for validation in Q1 FY25 and will cater to the uptick in volumes for the CDMO cardiovascular intermediate and the NCE opportunity in contrast media. Commercialization and an uptick in supplies are expected in Q2 FY25 as the new, larger capacity comes on-stream.
- Unit 3 Mahad delayed by a quarter: The plant will now be ready for validation batches in Q1 FY26, with no material sales revenue impact since the site is for import substitution of a currently imported product. A multipurpose block within Unit 3 will get validated by Q2 FY26.
- Unit 4 Greenfield is being upsized: The site master plan is submitted and all required approvals are in. The plan could be slightly larger than envisaged last year, replicating capacities for risk mitigation and higher customer needs. It is expected on stream in the second half of FY27.
- A larger capex plan is under evaluation: Seeing overall outsourcing trends in the CDMO business, management is evaluating a much larger capex plan and will update in coming quarters once formalized.
- Backward integration in Unit 3 adds margin control: The company is further backward integrating for a key intermediate, backed by a multi-year supply agreement, giving good control on an already profitable product.
PI-API and the Broader Pipeline: Fructifying Incubation
- Opportunities incubated 2-3 years back are now fructifying: The PI-API segment is seeing traction from past investments.
- A couple of launches are slated for FY25: Specific product introductions in the pharmaceutical intermediate segment are planned.
- Advanced-stage CNS and oncology opportunities: A couple of opportunities are at a very advanced stage, though management noted it will take some time for those to get commercialized.
- NCE intermediate on the gadolinium side is gaining solid traction: European approval has been received, and filings in other semi-regulated markets will drive future growth.
- Surge in RFPs from other innovators: Interest is rising across the focus areas of ecology, CNS, and cardiovascular health.
- New chemistry platforms expand the toolkit: Platforms added in FY24 include pyrophoric, iodination, enzymatic, and amino acid capabilities. A world-class pilot plant with versatile capability is under construction to improve speed of industrialization.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Contrast media volume recovery | Volumes return to historical levels after customer shutdown impact subsides | From Q3 FY25 onwards |
| Contrast media normalization | Normalization of supply to the largest customer | Q2 FY25 |
| Iodinated advanced intermediate scale-up | Scale-up of newly approved intermediate | During FY25 |
| Unit 2 Ambernath validation | Block ready for validation batches | Q1 FY25 |
| Unit 2 commercialization and supply uptick | Larger capacity on-stream, supplies increase | Q2 FY25 |
| Unit 3 Mahad validation | Plant ready for validation batches (one-quarter delay) | Q1 FY26 |
| Unit 3 multipurpose block validation | Block validated | Q2 FY26 |
| Unit 4 Greenfield on-stream | Site operational | H2 FY27 |
| Annual capex floor | At least ₹200 crores per annum | FY25 and FY26 |
| PI-API launches | A couple of product launches | FY25 |
| Employee cost increase | Significantly higher employee cost from senior hires and R&D expansion | FY25 |
| Gross margin mix shift | Gross margins may go down by a percent or two with higher PI-API growth | FY25 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue from operations (FY24) | ₹708 cr, degrowth of 1.3% vs ₹718 cr in FY23 |
| Q4 sales growth (QoQ) | 10% growth compared to Q3 |
| EBITDA (FY24, before extraordinary item) | 32.2%, improvement of 1.8% vs FY23 |
| EBITDA (Q4) | Dropped approximately 3.9% vs Q3, due to change in WIP and finished goods of ~₹27.4 cr |
| PAT (Q4) | 21.6%, improvement of 2.3% vs Q3 |
| PAT (FY24) | 23%, compared to 22.2% in FY23 |
| Extraordinary expense (Mahad incident) | ₹9.7 cr, classified as extraordinary item in FY24 |
| Contrast media revenue share (FY24) | ~68% of revenues |
| Pharma intermediates (CRAM) revenue share (FY24) | ~14% of business, grew ~156% year-on-year |
| ROCE | 26% |
| Fixed asset turnover | North of 5x |
| Capex spent (FY24) | Close to ₹200 cr, capitalized plus capital work in progress |
| Capex guidance (FY25 and FY26) | At least ₹200 cr per annum for the next two years |
| Capex outlay (three-year total) | ₹600 cr, increased from earlier estimate of ~₹500 cr |
| Renewable energy share | 60% to 70% of power requirement met from renewable sources |
| RFPs (pipeline indicator) | 2x of what they used to have |